Smith & Nephew Cuts Revenue Guidance to 4% Despite Strong Profit Growth in H1 2026
The UK medical device maker lowered its full-year revenue outlook while maintaining profit targets, citing US orthopaedics weakness and wound bioactives headwinds.
Revenue Growth Slows Amid Product-Specific Headwinds
Smith & Nephew plc reported first-half 2026 revenue of $3,097 million, representing growth of 4.6% including a 230 basis point foreign exchange tailwind, according to its 6-K filing submitted August 14. Underlying revenue growth reached 2.3%, or 3.1% on an average daily sales basis after adjusting for one fewer trading day versus the prior year (6-K filing, 2026-08-14).
The London-based medical device company reduced its anticipated full-year underlying revenue growth from approximately 6% to around 4%, while maintaining guidance for trading profit of around $1.3 billion post-acquisition, free cash flow of around $800 million, and adjusted return on invested capital exceeding 10% (6-K filing, 2026-08-14).
Second-quarter revenue totaled $1,597 million, with underlying growth of just 1.6%—"lower than we anticipated," the company stated in the filing. The shortfall was attributed to "temporary headwinds in US Hip Implants and ongoing challenges in US Knee Implants ahead of new product introductions" as well as "softer-than-expected performance from SANTYL within Bioactives" (6-K filing, 2026-08-14).
Profit Margin Expansion Through Efficiency Gains
Despite the revenue deceleration, Smith & Nephew delivered trading profit of $566 million in the first half, up 8.1% from the prior year, with trading profit margin expanding 60 basis points to 18.3% (6-K filing, 2026-08-14). Operating profit increased 4.3% to $448 million, while earnings per share rose 6.2% to 35.6 cents and adjusted earnings per share climbed 11.0% to 47.7 cents (6-K filing, 2026-08-14).
The company identified an additional $50 million in efficiency savings for 2026, bringing total anticipated savings to around $200 million for the year. Management also noted that tariff refunds are expected to fully offset the forecast tariff headwind, with the year-on-year impact now anticipated to be "broadly neutral to trading profit" (6-K filing, 2026-08-14).
Sports Medicine Strength Offsets Orthopaedics Weakness
The Sports Medicine division continued to show momentum, with joint repair revenue growing 11.8% in Q2, driven by double-digit growth in the REGENETEN Bioinductive Implant and Q-FIX KNOTLESS All-Suture Anchor (6-K filing, 2026-08-14). Multiple product platforms delivered double-digit or higher growth, including CATALYSTEM, AETOS, CARTIHEAL AGILI-C, FASTSEAL, and LEAF (6-K filing, 2026-08-14).
Conversely, the Orthopaedics segment declined 0.2% in Q2, with US Knee Implants down 7.2% as the company awaits the third-quarter launch of the cementless version of its LANDMARK Knee System (6-K filing, 2026-08-14). US Hip Implants fell 1.5% following four consecutive quarters of above-market growth, though the company expects a return to growth driven by increased CATALYSTEM set deployment (6-K filing, 2026-08-14).
Advanced Wound Management revenue decreased 1.6% in Q2, impacted by changes to US reimbursement rules for skin substitutes that took effect in early 2026, creating an expected headwind "towards the upper end of the previously guided $20 to $40 million range" (6-K filing, 2026-08-14).
Cash generated from operations reached $605 million in the first half, up 6.9%, supporting a $500 million share buyback program announced in May, with $216 million settled as of August 3. The company increased its interim dividend 4.0% to 15.6 cents per share (6-K filing, 2026-08-14). MarginX data shows the dividend is payable October 1, 2026, with third-quarter results expected November 5, 2026.
This article was generated by MarginX from the 6-K filing on 2026-08-14. It is not investment advice.